Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewAmsterdam Pharma Company N.V. filings document a late-stage clinical biopharmaceutical issuer developing oral, non-statin therapies for cardiovascular-risk patients with elevated LDL-C. Its Form 8-K reports furnish financial results, corporate updates, investor presentations and clinical-program disclosures involving obicetrapib, including its use alone and with ezetimibe.
The company’s SEC record also covers proxy governance, executive compensation, equity awards, director and officer matters, compensatory arrangements and Nasdaq-listed securities. Cover-page disclosures identify ordinary shares under NAMS and warrants under NAMSW, while material-event filings record Regulation FD presentations, leadership-related agreements and public-company capital-structure information.
NewAmsterdam Pharma’s Chief Accounting Officer Louise Frederika Kooij reported an exercise-and-sell transaction in Ordinary Shares. On May 26, 2026, she exercised options to acquire a total of 65,000 shares at exercise prices of $10.00 and $10.90 per share.
That same day she completed an open-market sale of 65,000 Ordinary Shares at a weighted average price of $35.69, with individual trades ranging from $35.12 to $36.09 per share. After these transactions she directly holds 24,353 Ordinary Shares, including 22,000 shares subject to restricted stock unit awards that continue to vest over time.
NewAmsterdam Pharma Company N.V. reported that Bain Capital Life Sciences–affiliated funds significantly reduced their position and now hold under 5% of the company’s ordinary shares. After recent sales, the group may be deemed to beneficially own about 2.2 million ordinary shares plus warrants and pre-funded warrants representing roughly 3.3% of the outstanding shares.
On multiple dates in May 2026, BCLS Fund III and BCLS II Investco sold sizeable blocks of NewAmsterdam ordinary shares, including a May 12, 2026 transaction under Rule 144 totaling 2,900,000 shares for aggregate consideration of about $107.9 million at a weighted average price of $37.22 per share. Following these sales, the reporting persons ceased to beneficially own 5% or more of NewAmsterdam’s outstanding ordinary shares.
NewAmsterdam Pharma reported first quarter 2026 results and a broad clinical update. Revenue was $3.0 million, while net loss widened to $48.4 million from $39.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026.
The company highlighted ongoing Phase 3 programs for obicetrapib, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled, REMBRANDT with 323 patients enrolled, and RUBENS targeting about 300 patients. Interim PREVAIL analysis is planned for 4Q 2026 with results expected in 1Q 2027.
Regulatory decisions in Europe, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed‑dose combination are expected in 2H 2026, with potential launches by Menarini in 4Q 2026 in Germany and the UK. The company also described Alzheimer’s biomarker findings from the BROADWAY trial and plans a new trial in early Alzheimer’s disease in 2026.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.
NewAmsterdam Pharma Company N.V. is asking shareholders to vote at its June 2, 2026 annual general meeting in Amsterdam on nine proposals covering financial statements, governance and compensation.
Shareholders are asked to adopt the Dutch statutory annual accounts for 2025, discharge directors from liability for 2025, and instruct and ratify Deloitte Accountants B.V. as external auditor and independent registered public accounting firm for 2026. Two non-executive directors, John W. Smither and Janneke van der Kamp, are up for reappointment with proposed terms running until the 2030 annual meeting.
The agenda also seeks to extend the Board’s authority to issue ordinary shares and to limit or exclude pre-emption rights for up to five years, approve a 2026 Employee Stock Purchase Plan reserving 1,150,000 ordinary shares, and hold a non-binding advisory vote on 2025 compensation for named executive officers. Shareholders of record as of May 5, 2026 may vote in person, by proxy, telephone or internet, subject to the described deadlines and procedures.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. is soliciting proxies for its 2026 Annual General Meeting to be held on June 2, 2026 at 5:00 p.m. CEST in Amsterdam. The agenda includes adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2025, discharge of directors, auditor instruction and ratification, director reappointments, extensions of authorizations to issue ordinary shares and to limit pre-emption rights, approval of a 2026 Employee Stock Purchase Plan (ESPP) reserving 1,150,000 ordinary shares, and a non-binding advisory vote on 2025 executive compensation.
The Record Date is May 5, 2026; Beneficial Owners must submit an Attendance Notice and supporting proof by 11:59 p.m. ET on May 31, 2026 (Cut-off Time). Audit fees paid to Deloitte were $1,071,000 for 2025 and $1,433,000 for 2024. Proxy voting options, quorum rules and vote thresholds for each proposal are described in the proxy materials.